Fig. 5.
Enhanced activity of the RAS-MAPK signaling pathway due to the loss-of-function mutation of the NF1 gene and mode of selumetinib action. MAPK, mitogen-activated protein kinase; ERK, extracellular-signal-regulated kinase.
Enhanced activity of the RAS-MAPK signaling pathway due to the loss-of-function mutation of the NF1 gene and mode of selumetinib action. MAPK, mitogen-activated protein kinase; ERK, extracellular-signal-regulated kinase.